12:00 AM
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

BioTime, Geron deal

BioTime's BioTime Acquisition Corp. subsidiary will acquire Geron's discontinued stem cell programs consistent with the financial terms outlined in the letter of intent signed by the companies last November. The companies...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >